Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05266872

Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme

The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic", Luxembourg

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
  • Subjects of all genders with a full capacity of consent
  • Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
  • Subjects of at least 18 years of age at the time of inclusion

Exclusion criteria

  • Refusal to sign the informed consent
  • Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
  • Active cancer
  • Pregnant women
  • Underage subjects of less than 18 years of age
  • Refusal to comply with mandatory sample collection
  • For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.

Treatment and study plan

Observational study with sample and data collection

Other

Observational study with sample and data collection

Primary outcomes

  1. 1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls

    Time frame: through study completion, an average of 8 years

    1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.

  2. 2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.

    Time frame: through study completion, an average of 8 years

    2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.

  3. Determine Parkinson's disease biomarker signatures

    Time frame: through study completion, an average of 8 years

    3.1. Identify new and early diagnostic biomarkers

  4. Develop a mechanistic understanding of the disease

    Time frame: through study completion, an average of 8 years

    4.1. Understand the mechanisms of PD pathogenesis.

Secondary outcomes

  1. Inform future studies testing new therapies for Parkinson's disease

    Time frame: through study completion, an average of 8 years

    1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets.

  2. Harmonization of data with international Parkinson's disease cohort studies

    Time frame: through study completion, an average of 8 years

    2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform.

Study contacts

Contact information is provided by the study sponsor or research team.

Parkinson clinic

CONTACT

[email protected]

+352 44 11 4848

Rejko KRÜGER, Dr

CONTACT

[email protected]

+352 44 11 4848

Sponsors and collaborators

Lead sponsor

Luxembourg Institute of Health

Other Gov

Collaborators

  • Centre Hospitalier du Luxembourg
  • Laboratoire National de Santé (LNS)
  • University of Luxembourg

Registry information

Official study title

Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)

Acronym: LuxPARK

Important dates

Study start
2014
Primary completion
2025
Study completion
2025
First posted
Mar 4, 2022
Registry last updated
Aug 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.